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Although the 103rd Congress, despite much anticipation, did not enact any
health care reform legislation, many of the problems which led to proposals
and consideration of reform still remain. Health care costs are still increasing,1
though growth has slowed.2 Large portions of the United States population
remain uninsured or underinsured.3 It would not be surprising if some form of
health care reform reappeared on the scene some time in the near future.
In this paper, I discuss one element of government health care cov-
erage which must be considered as part of any comprehensive health care reform
eort  o drug coverage.4 Drugs are an important part of health coverage, and
are likely to become even more signicant5 Payments for drugs were approxi-
mately 8.1 percent of total health care expenditures in 1991, totaling over $60
1Carolyn S. Donham, HEALTh CAREFIN. REv., Summer 1994, at 165,190.
2Id.
3Approxiinately 14 percalt were not covered by health insurance in 1991. 1995 WORLD
ALMANAC & BOOK OF FAcrs 967(1994).
4I concentrate on coverage issues rather than picing issues because the former have more
relation to Food and Drug Law and because I can only cover ~ much. This is not to say
that pricing issues, such as required rebates under Medicaid, are inelevant to a comprehensive
examination of governn~it reimbursement of drugs. However, that paper will have to wait for
another time.
5Sean D. Sullivan et al., The Economics of Outpatient Drug Coverage for the Elderly:
Implications for Healthcare ~ GENERATIONS, June 22, 1994, at 55 (noting tint most chronic
diseases attacking older people are controllable through drugs).
1billion.6 In addition, drugs are intricately involved with many of the problems
which people see as requiring reform. Drug prices, like the cost of health care in
general, have increased at a much faster rate than other prices in the economy
since 1980.7
Insurance coverage of drugs, both public and private, varies con-
siderably.8 Although the elderly population is one of the major consumers of
drugs,9 Medicare, the primary elder insurance plan, does not generally provide
coverage for prescription drugs.10 Drug reimbursement under government in-
surance has been debated since the initial passage of the Medicare and Medicaid
legislation.11 Congress reexamined the issue throughout the 1970s and 1980s.12
Drug coverage under Medicare was actually provided in the Medicare Catas-
trophic Coverage Act of 1988,13 but then rescinded when most of the act was
repealed a year later.14 Drug coverage was proposed as a benet for both the
Comprehensive Benet Package under the Alliances and under Medicare as part
of President Clinton's proposed Health Security Act of 1994.15 States have the
option under Medicaid to cover drugs, and most do.16
65.W. Letich, National Health Care Spending in 1991, HEALTH AFF., Spring 1993, at
94,96-98. Of this $60 billion, $36 billion was for prescription drugs while $24 billion was for
non-prescription drugs and other medical nondurables. Ii
7Sullivan, ~g note 5, at 55. However, nonprescription drugs appear to have a much slower
ination rate. 5~ Letsch, supa note 6, at 98.
8Sullivan. ~ note 5.
9Sullivan. note 5.
1021-42 and accompanying text.
11Stephen H. Long, Prescription Dnigs ami the Elderly: Issues and Options, HEALTh AFF.,
Spring (11)1994, at 157, 158.
12Id.
13Thjb. L No. 100-360,102 Stat. 702 (1988). See notes 70-74 and accompanying text
14Medicare Catastrophic Coverage Repeal Act of 1989, Pub. L. No. 101-234, 103 Stat.
1979(1989).
15H.R. 3600/S.1757, 103d Cong., 2d Seas. (1994). See notes 56-69 and accompanying text.
16See notes 43-55 and accompanying text.
2The paper is divided into three sections. In the rst section, I de-
scribe four dierent public sector schemes for government coverage of drugs.
First I outline the existing drug coverage system under the two dominant gov-
ernment health care programs, Medicare and Medicaid. I then outline proposals
contained in the Medicare Catastrophic Coverage Act of 1988 and the Health
Security Act of 1994. The second section examines coverage dierences between
the four schemes and shows where each plan allocates exibility regarding cov-
erage issues. The nal section addresses some of the dicult issues surrounding
drug coverage, and discusses whether and how the four schemes described ad-
dress these issues. I examine three problems: (1) Should drugs be covered at all
under a government health insurance plan? (2) How should coverage be related
to approval by the Food and Drug Administration? and (3) How should over
the-counter drugs be treated? While this discussion may not denitively show
how a future drug benet should look, it does outline a number of issues which
should be taken into account.
I.A Description of Four Drug Reimbursement Systems
Of the four drug reimbursement systems described below, all but
the Clinton Plan deal exclusively with government reimbursement. (The Clinton
Plan also includes a drug benet in its Comprehensive Benet Plan applicable
to all health plans.) However, drug reimbursement is obviously an issue with
relevance to private as well as public insurers.17 There are a number of reasons
for focusing on public insurance. Public insurers are quite large and are often
17willy~ Linda C. Higgins, O-lahel Rx: Insurers Starting to Balk MED. WORLD NEWS,
Oct. 24,1988, at22.
3industry leaders when change happens.18 This is especially true for the elderly,
who are large users of prescription drugs. Also, focusing on public insurance
provides a simplied way to examine reimbursement issues. Finally, legislative
reform is most likely to aect the public sector (barring passage of comprehensive
health care legislation).
The rst two descriptive summaries require a brief introduction.
Medicare and Medicaid are both government-run health insurance systems, but
are administered in very dierent ways. Medicare is targeted primarily at the
elderly and disabled population and is funded and administered by the Federal
government. Medicaid is targeted primarily at the poor and is jointly funded and
administered by the Federal government and individual stales. As a result, while
Medicare benets are relatively uniform across states, Medicaid benets vary
widely both in scope and in degree.19 However, the Federal government does
set minimum standards for the Medicaid program. Both programs utilize local
insurers (usually Blue CrosslBlue Shield or Aetna) to provide actual payments
to providers.20
Medicare is divided into two separate programs, Part A
and Part B.21 Part A deals primarily with facility-based in-patient care, while
18Private insurers may even defer to Medicare determinations for coverage decisions. ~, ~
Bechtold v. Physicians Health Plan, 19 F.3d 322(7th Cir. 1994).
19 ~g~~y Terry S. Coleman, U~E&fr ~xmAm.Ba~1g.Baim~1ra~menLkEI, 44FOODDRUG-
COSM. U. 99(1990).
20There are a number of dierent terms used for insurers which distribute Medicare and
Medicaid nids (carriers, intermediaries, and in some cases liMOs and other managed care
organizations). Rather than parse these words into their specic technical meanings, I use
carrier and scal intermediary interchangeably.
21The Medicare program as a whole is codied at 42 U.S.C.A. x* 1395-1395ccc (West Supp.
1994). Part A is described primarily at 42 U.S.C.A.I~ 1395c-1395i-4 (West Supp. 1994), while
Part B is at 42 U.S.CA. xx 1395j-1 395w-4 (West Supp. 1994).
4Part B deals with out-patient care and physician reimbursement. Part B re-
quires a premium payment. Drugs are treated dierently under the two dierent
Parts, though the denition of a drug is dened statutorily for both sections.
To fulll the Medicare denition of a drug, the drug must be either included, or
approved for inclusion, in one of the ocial drug compendia22 or be approved
by the facility medical sta's pharmacy or drug therapeutics committee.23 FDA
approval automatically fullls the statutory requirement when used for the ap-
proved indication.24 The statute provides an explicit exception for anti-cancer
chemotherapeutic cancer drugs, which have been approved for a medically ac-
cepted indication and distributed by the National Cancer Institute.25 Reim-
bursement under Medicare must also be reasonable and necessary.26 Carriers
under Medicare have signicant discretion in deciding what type of drugs are
reasonable and necessary in the absence of HCFA direction.
Under Part A, drugs are generally covered when provided as a ben-
et incident to a hospital visit. However, they must be furnished for use in
the institution, must represent a cost to the institution, must be ordinarily fur-
nished,27 and must t the Medicare denition of a drug. In general, this means
that investigational or nonapproved drugs are not reimbursed.28 However,
22Compendia include: (a) the U.S. Pharmacopoeia, (b) the Natiouial Formulary, (c) the
U.S. Homeopathic Pharmacopoeia, (d) AMA Drug Evaluations, and (e) Accepted Dental
Therapeutics. Medicare and Medicaid Guide(CCH) @ 1223 (Aug. 4,1994). This is essentially
an updated version of the list given at 42 U.S.C.A. 5 1395x(tXl) (West Supp. 1994).
2342 U.S.C.A. x 1395x(tXl) (West Supp. 1994).
24Medicm and Medicaid Guide (CCII) @1223 (Aug. 4,1994). These are the Omup C drugs.
2542 U.S.CA x 1395x(tX2) (West Supp. 1994). S~ahaQ Medicare and Medicaid Guide
(CCH) @ 27,201 (Aug. 28, 1994).
2642 U.S.C.A. x 1395y(aX 1) (West Supp. 1994).
2742 CFR 5409.13 (1993).
28Medicare and Medicaid Guide (CCH) @ 1223 (Aug. 4,1994).
5unapproved uses of approved drugs may be allowed depending on
the generally accepted medical practice in the community.29
Under Part B, prescription and non-prescription drugs purchased
are not covered by Medicare, unless furnished by a physician30 and fullling
the Medicare drug denition. There are a number of statutory exceptions to
this general rule. For example, Group C cancer drugs, as mentioned above,
are reimbursable under both Part A and Part B.31 Other exceptions include
u, pneumococcal and hepatitis B vaccines, some antigens, immunosuppressive
drugs, and osteoporosis drugs (until December, 1995).32 However, a notice of
hearing by the Food and Drug Administration (FDA) under the Federal Food
Drug and Cosmetic Act (FFD&CA) x 50533 regarding withdrawal approval for
a drug (or a similar drug) not subject to the 1962 Drug Amendments34 precludes
reimbursement under Part B.35 This restriction does not apply to Part A.36
In many ways the most controversial portion of the Medicare drug
coverage requirements has been the general Medicare requirement that reim-
bursement be reasonable and necessary.37 HCFA has interpreted this to mean
29y~ ~ Coleman, supra { ~ at ~
30Medicare and Medicaid Guide (CCII) @ 3126 (Nov. 3,1994).
3142 U.S.C.A. x 1395x(tX2) (West Supp. 1994). ~al~ Medicare and Medicaid Guide
(CCII) @ 27,201 (Aug. 28, 1994).
3242 U.S.C.A. x 1395x(sX2) (West Supp. 1994).
332l U.S.C.A. x 355.
34Under x 703(cX3) of the Drug Amemiments of 1968, Pub. L 87-78 1 (1962).
3542 U.S.C.A. x 1395y(c) (West Supp. 1994).
36M~li~ and Mudicaid Guide (CCII) @ 1223 (Aug. 4,1994).
37A number of cases have been litigated contesting HCFA's determination of whether a
drug was reasonable and necessary. ~, ~, Friedrich v. H.H.S., 894 F.2d 829(6th Cir. 1990)
(rejecting plaintis claim that Medicare decision not to cover chelation was in contravention
of the reasonable and necessary standard); Pulmocare Pharm. v. Sullivan. CV No. 91-
1291-PA, 1992 U.S. Dist. LEXIS 14528 (D. Ore. l992Xupholding HCFA decision to not
reimburse drug after FDA notied company of its lack of approval); National Council of
Senior Citizens v. Hams, No. 80-157, MEDICARE ANDMEDICAID GUIDENEWDEV.
@30,636,(D.D.C. Aug.27, 1980) (upholding HCFA decision to reimburse despite FDA action
questioning eectiveness. This predated HCFA regulations that would now require action).
6that the item in question must be (1) safe and eective, (2) not experimental
or investigational, (3) cost-eective, and (4) appropriate.38 If HCFA has not
made a national coverage decision, the decision is left to the carriers)39 Though
experimental or investigational use drugs are not reimbursed by Medicare, the
unapproved use of many FDA approved drugs is left to the Medicare carriers.
Proposed Medicare rules state that breakthrough procedures are judged by a
less stringent standard,40 but it is unclear whether this applies to drugs as well
as procedures.
Some cases have also addressed the question of whether HCFA
regulations unlawfully interfere with the practice of medicine in violation of the
Medicare statute.41 However, these cases have not met with much success.42
BJM~
Because Medicaid43 is primarily administered by the states, much
variation exists regarding precise coverage of certain benets. In fact, prescrip-
tion drugs are an optional benet under Medicaid. On the other hand, some
In all of these cases, the court upheld HCFA's determination of what is and is not reasonable
and necessary. ~g Hultmian v. Weinberger, 495 F.2d 1276(1974) (holding that the Secretary
may not deny coverage retroactively when he believes the utilization review committee did
not function properly).
3854 Fed Reg. 4302,4307 (1989) (to be codied at 42 C.F.R. x 405.380) (proposed Jan.
30, 1989) (No nal rule has been promulgated). It was actually the settlement of a
lawsuit which rst provided HCFA with the impetus to propose regulations outlining the
determination process for reasonable and necessary. Id.
39Id.
40Id.
41Nothing in this subchapter shall be constmed to authorize any Federal ocer or
employee to exercise and supervision or control over the practice of medicine or the manner
in which medical services are provided.... 42 U.S.C.A. x 1395.
42~, ~g,, American Medical Ass'n v. Mathews, 429 F. Supp. 1179,1201.03 (N.D.
Ill. 1977) (holding that MAC regulations for drug reimbursement don't interfere enough to
came a violation). S mla~ Goodman v. Sullivan, 891 F.2d 449(2nd Ct. 1989) (holding that
Medicare was not required to pay for MRI procedure despite recommendation of physician).
43The Medicaid program is codied at 42 U.S.C.A. xj 1396-1396v (West Supp. 1994). ~42
U.S.C.A. x 1396r-8(kX2) (West Supp. 1994).
7states may choose to cover non-prescription drugs.
The Federal government provides guidelines for states which choose
to provide drug benets. One baseline is the statutory denition of covered
outpatient drug.44 The statute states that the drug must be available only by
prescription45 and must either be (1) FDA- approved,46 (2) a pre-1962 drug (or
a similar drug) which has not been determined to be a new drug or to have in-
adequate directions for use, or (3) a drug to which the 1962 Amendments do not
apply47 (and for which approval has not been withdrawn). The denition also
includes prescription biological products (other than vaccines) and insulin drugs
certied under x 506 of the Federal Food Drug & Cosmetic Act. The denition
explicitly excludes drugs used for a medical indication which is not medically
accepted48 A medically accepted indication is either the FDA-approved use or
a use supported by a compendia.49
States are allowed to limit coverage beyond the denition of covered
outpatient drug.50 Restrictions or exclusions are allowed for a particular list of
reasons.51 The state may also choose to create its own formulary52 or require
44Id.
45States may choose to expand this denition to also include nonprescription dregs.
42 U.S.C.A. x 1396r o8(kX4) (West Supp. 1994).
46Federa1 Food Drug & Cosmetic Act of 1938 xx 505,507, codied at 21 U.S.CA. xx 355,
357.
47Drug Amendments Act of 1962, Pub. L No. 87-781, x 107(c)(3).
4842 U.S.C.A. x 1396r-8(kX3) (West Supp. 1994).
4942 U.S.C.A. x 1396r-8(kX6) (West Supp. 1994). Compendia allowed for this
purpose include the American Hospital Fornudmy Service Drug Information, the
U.S. Pharmacopoeia-Drug Information, and the Amican Medical Associate Drug
Evaluations. 42 U.SC.A. x 1396r-8(gXlXBXi) (West Supp. 1994).
5042 U.S.C.A. x 1396r-8(d) (West Supp. 1994).
51These include anorexia and weight loss drugs, fertility drugs, hair growth drugs, nonpre-
scription drugs, ami vitamins. 42 U.S.C.A. I 1396r-8(dX2) (West Supp. 1994).
5242 U.S.C.A. x 1396r-8(dX4) (West Supp. 1994).
8prior approval for drug coverage.53
Unlike cases arising under Medicare, plaintis have generally had
more success in requiring Medicaid to reimburse drugs despite initial coverage
denials, if medically necessary.54 This is true even for uses unapproved by
FDA.55
C.Medicare Catastrophic Coverage Act of 1988
The Medicare Catastrophic Coverage Act of 1988 (MCCA) pro-
vided for a number of new Medicare benets, including drug coverage, largely
designed to expend coverage for the elderly.56 Although the statute was short-
lived and the benet never implemented, we do have a relatively clear outline
of the proposed benet from the statute, legislative history and proposed regu-
lations.
The basic statutory denition57 of a covered outpatient drug is es-
sentially taken from the Medicaid statute.58 The statute further excludes certain
services aiready covered elsewhere in the Medicare statute.59 The statute states
that the Secretary shall establish for each outpatient drug standards which
are based on accepted medical practice.60 These standards shall incorporate
5342 U.S.C.A. x 1396r-8(dXlXA) (West Supp. 1994).
54~.g,, Weaver v. Reagen, 886 F.2d 194(8th Cir. 1989) (holding that Missouri
must reimburse AZT when physicians had certied that treatment was medically
necessary).
55886F.2dat 198.
56John K. Iglehart, Medicare's New Benets~ Catastrophic Health Imurnm~~ 320 NEW
ENG. J. MED. 329, 329-30(1989).
57MCCA, Pub. L No. 100-360, x202(a)(2XC), 102 Stat. 702-03(1989).
58Comvar~ 42 U.S.C.A. x 1396r-8(kX2) (West Supp. 1994). This language is actu-
ally broader than either the House or Senate bills' language had been. H. Conf.
Rept. No.100-661,100th Cong., 2d Sees. 185(1989) (Conference Report), r~intuIia
1989 U.S.C.C.A.N. 923,963.
59MCCA, Pub. L No.100-360, x202(a)(2XC), 102 Stat. 703 (1989).
60MCCA, Pub. L No. 100-360, x2(12(b)(4), 102 Stat 708-09(1989).
9authoritative compendia61 modied by scientic and medical information that
such standard is not consistent with the safe and eective use of the drug.62 The
statute explicitly prohibits the creation of a Medicare formulary.63 The reason-
able and necessary statutory requirements already contained in the Medicare
statute would also still apply.64
The Health Care Financing Administration (HCFA) Notice of Pro-
posed Rulemaking placed in the Federal Register following passage of the MCCA
gives further indications of how the MCCA drug benet would have been im-
plemented. For example, the proposal makes clear that, unlike Medicaid, pre-
scription drug really means only prescription drugs and may not include non-
prescription drugs.65 The proposed regulations conrm that drug standards
promulgated under the act will use the three compendia mentioned in the Con-
ference Report66 and that any deviation from the compendia must use rule-
making procedures.67 The proposed regulation asserts that payment may not
be made for specic uses which HCFA nds are not safe and eective for the
diagnosis or treatment of illness or injury.68 However, the proposal also states
that standards would not be used to dene coverage or payment of covered
61P~ Conference Rq~ort expects that compendia will include the U.S. Pharmacopoeia Dis-
pensing Information, the American Medical Association's Drug Evaluations, and the American
Hospital Formulary Service Drug Information. Conference Report at 192, r~axiatmIin 1989
U.S.C.C.A.N. 923,970.
62MCC~ Pub. L No. 100-360, x202(bX4), 102 Stat 709(1989).
63~
64notes 37-40 and accompanying text. Also noted in Conference Report at 191,
r~xin1ad.iu 1989 U.S.C.C.A.N. 923,969.
6554 Fed. Reg. 37,196(1989).
6654 Fed Reg. 37,208(1989) (to have been codied at 42 C.F.R. x 410.32) (proposed
Sept. 7, 1989).
67Id.
6854 Fed Reg. 37,207(1989) (to have been codied at 42 C.F.R. x 410.30(d)) (proposed
Sept. 7, 1989).
10outpatient drugs under the Act.69
D. The Clinton Health Security Act
On October 27,1993, President Clinton presented his Health Secu-
rity Act of 1994 (HSA) to Congress. Even though the legislation was eventually
not acted on by Congress, it was extensively analyzed in both academic settings
and in the media and thus provides another possible model of prescription drug
coverage under a government plan. However, because the legislation was not
enacted nor eshed out, the terms are substantially more vague than an enacted
statute (MCCA) or existing programs (Medicare, Medicaid).
Inmanyways,theClitonpla15atlea5ttwoplan5inoneforthePI1~OseSofdrug
coverage. Drugs are included as a new benet under Medicare and are also in-
cluded as part of the Comprehensive Benet Package which would be a oor for
health packages guaranteed to the general public.
The new benet under Medicare, like the new benet proposed un-
der the MCCA, adopts the Medicaid denition of a covered outpatient drug.70
However, the HSA denition of medically accepted indication is slightly ex-
panded from the Medicaid and MCCA denitionL Under the HSA, medically
accepted indication includes uses (1) for which the drug has been approved for
use by the FDA and (2) other uses if the drug has been approved by the FDA
and either the use is supported by the usual compendia71 or the carrier involved
determines that such use is medically accepted based on peer review medical
6954 Fed. Reg. 37,200(1989).
703600/5. 1757, 103d Cong., 2d Sess. (HSA) x 2001(2Xb)(3) (1994).
71hi this case the U.S. Pharmacopoeia - Drug Information, the American Medical
Association Drug Evaluatione, and the American Hospital Forinulary Service -
Drug Information. Id8
11literature.72 As in the MCCA, the legislation provides for promulgation of out-
patient drug standards based on compendia and modication by regulation.73
The drug benet in the Comprehensive Benet Package refers to
the (amended) Medicare denition of covered outpatient drug and medically
accepted indication except that the Secretary (the Board in an earlier draft) is
substituted for the carrier in determining whether a use is medically accepted
based on clinical evidence in peer review medical literature?74
II.An Analysis of Dierences Between the Four Drug Coverage
Schemes
To a large extent the dierences between the four drug coverage
schemes are minimal. Three of the four (Medicaid, MCCA and HSA) essentially
dene a covered outpatient drug in the same manner. All utilize FDA approval
as a way of certifying a drug's safety and eectiveness to some extent However,
there are signicant dierences both between the MedicaidIMCCAIHSA deni-
tion and Medicare's drug denition and among all four in terms of how much
exibility the government has in dening drug coverage.
The Medicare denition of drug, at least textually, appears to be
broader than the other denitions. While the MedicaidIMCCA/HSA denitions
state that a drug (1) must be a prescription drug and (2) must either be FDA-
approved or not otherwise FDA-disapproved (i.e. a pre-1962 old drug or a drug
to which the 1962 Amendments did not apply), further coverage requirements
allow reimbursement for medical accepted indications as dened either by FDA
72Id.
73H5A x 2002(a) (1994).
74H5A x 1 122(aX2).
12approval or by inclusion in a compendia. The Medicare drug denition looks
rst to either compendia or approval by a medical sta FDA approval for the
approved use counts as if in the compendia.
Examining these two denitions textually, there are a few possible
points of departure. First, a drug may be recognized as a drug by an applicable
compendia but which is not approved by FDA. This type of drug would more
likely be reimbursable under Medicare than under the MedicaidIMCCA/HSA
denition. Similarly, a drug which is disapproved by the FDA may still be eligi-
ble for reimbursement under Medicare Part A (though Part B makes a specic
exclusion for this situation) if either the drug is included under a compendia
listing or the medical sta thinks the drug should be included in treatment On
the other hand, since Medicare reimbursement is limited to those treatments
which are reasonable and necessary, this may even out some of the possible
inequities. For example, experimental drugs are excluded under Medicare's
reasonable and necessary standard, but may nevertheless be covered under the
MedicaidIMCCAIHSA denition This is similarly true with drugs which are not
cost-eective. Finally, and in some ways most importantly, because Medicare
is limited to facility-based care and generally excludes self-administrable drugs,
many more outpatient prescription drugs are and would be approved under the
MedicaidIMCCAIHSA schemes.
Among the MedicaidIMCCAIHSA denitions, HSA's denition of
medically accepted indication provides slightly more discretion than the other
two because it permits carrier discretion to approved reimbursement for uses
13ways less exible than Medicare. Medicaid plans can also require prior approval
systems.
MCCA, while using the Medicaid denition of a drug, did not oer
the same kind of exibility as Medicaid. However, since it was designed as an
addition to the Medicare program, drugs would still be subject to the reason-
able and necessary statutory requirement Some exibility issues are simply not
clear. Although the statute calls for HCFA to investigate the safety and eec-
tiveness of drugs independent of FDA's determination, establish standards for
each outpatient drug, and to not make payment for uses that HCFA nds are
not safe and eective, the statute also prohibits the creation of a formulary and
regulations conrm that though rulemaking proceedings would be necessary to
deviate from standards derived from accepted medical compendia, standards
would not be used to dene coverage or payment. Thus is unclear how much
discretion HCFA would have had in setting coverage boundaries had the MCCA
plan been implemented.
The HSA, as in the present Medicare system, would have given
signicant exibility to carriers to determine coverage if HCFA, the FDA, and
compendia do not address coverage. However, like the MCCA, the HSA pro-
vided for outpatient drug standards. Unlike the MCCA, there is no explicit
prohibition against either having a formulary or against using the standards to
dene coverage. Interestingly, the health care benet oered under the com-
prehensive benet package does not delegate analogous authority to address
705 F. Supp. 520 (D. Kan. 1987) (forcing AZT to be included in Kansas' Medicaid
formulary).
15coverage vacuums to insurers (the logical analogy to carriers) but rather to the
Secretary of HHS. This essentially means that, assuming that some plans opt
for a minimal drug benet, that the Medicare benet may be more inclusive
(based on carrier discretion) than the minimum comprehensive benet package.
III.Some Important Coverage Issues Regarding Government Drug Reimbursement
In this section 1 examine a number of the most important cover-
age issues surrounding provision of a drug benet under a government health
insurance plan. The discussion is organized topically into three questions, but
issues involved in responding to the questions necessarily overlap. For example,
cost-containment is a concern for all three questions.
A. Should a drug benet exist at all?
In many ways it is a reasonable question to ask whether a drug
benet should exist at all. Although there may be need, particularly among
some elderly, won't a benet simply wind up costing too much money to im-
plement? Won't people overutilize covered drugs? Perhaps our money could be
better spent elsewhere. Medicare Part B has survived without a drug benet~
These are not meritless arguments. Nevertheless, numerous studies
have shown that the market for medical drugs is a favorable one for insurance.77
Drug spending among the elderly is a skewed distribution. The 11 percent who
spend the most on drugs account for nearly half (45 percent) of total drug
spending?78 As long as these high costs are not foreseeable, it makes sense to
have insurance to spread the risk279Especially in terms of a national health plan
77Long, ~j note 11 at 159.
78Id.
79soma point risk does become obvious, and then adverse selection (the idea that
16that includes all elderly (thus discouraging adverse selection), it appears to make
sense to have insurance. In contrast, the present system forces many to pay for
drugs out-of-pocket; 55 percent of the $36 billion paid for prescription drugs in
1991 was paid without insurance.80 There is also a serious disparity between
those that do and do not have insurance. Most of the elderly that do have drug
insurance have it through employer-sponsored plans.81 Thus, as elders move
out of the work force, they are likely to lose prescription drug coverage when
they most need iL Although Medicaid often covers drup, this is only applicable
to the poorest in society.
A prescription drug benet would likely increase utilization of drugs.82
However, this is not necessarily a bad thing. Studies have shown that increased
utilization from a drug benet has gone more to fulll unmet need than toward
overutilization.83 This makes sense since, given the present system (for many el-
ders) where medical procedures are covered by insurance but prescription drugs
(which could avoid the need for costly procedures) are not, people are less likely
to take drugs (since they'd have to pay) and instead opt for the costly proce-
dures (for which they won't have to pay) later. In lbct, using this logic, some
studies have shown that imposed limits on drug coverage in some cases resulted
in an actual increase in health care costs and increased institutionalization of
only those who need the insurance - the high risk high cost people - will purchase
insurance, thus 6iling to spread risks at all) is a wony.
80Id. This is in fact one of the argun~nts for required or universal health insurance. If ~u
purchase insmrance before risks are clear, there is no adverse selection possibility.
811d.at 161.
82M. Greenlick & D. Benjamin, with UtilizAtion Under a Drug Prep~,ment Plan
58 AM. J. PUB. HEALTH 2121(1968), A. Liebowitz et aL, Iho21 Soc Sc!. & MED. 1063,
lxplh~itmt in Sullivan, note 5.
83G~iiJick & Bem~jamin, uiiwn note 82.
17the elderly.84
As a result of this evidence, it seems to make sense that insurance
for drugs should at least be considered under any future health care reform,
particularly for the elderly who are the largest users of prescription drugs. The
present Medicare system of not having a drug benet may actually be costing
the health care system more in the long run. A secondary benet to drug
coverage is that it may encourage increased innovation by drug companies to
develop new drugs. Because there will be increased utilization, drug companies
will have more resources and incentives to nd new drugs. However, this is
by no means certain. In fact, the Pharmaceutical Manufacturers Association
actually fought against the MCCA drug benet because along with prescription
coverage came strict price controls.85 Thus the eect on the pharmaceutical
industry is not clear.
B. How should coverage be related to FDA approval?
Even if drugs are covered under a health insurance plan, there is
still a question of which drugs should be covered. One of the most important
questions in this vein is what relation FDA approval should have to coverage.
There are a number of dierent possibilities, ranging from covering only uses for
which drugs were approved by FDA to deferring to physician discretion. Present
coverage benet proposals have generally been somewhere in the middle of these
84Stephen B. Soumeiui et al., Eects of Medicaid Dnmg-Pavmamt Limits on
Admission to Hcuspitals ami Nummg lj~, 323 NEW ENG. J. MED. 1072(1991).
~ alma E.W. Lingle et al., Ihn.ILaL~fhfg~m3~ on the Use and Costs of Health Care
Services for the Elderly. INQUIRY, Fall 1987, at 203, ~i1ml in Sullivu~, uu~a note
5.
85lglehart, ~ note 56, at 333; ~ CHAIN DRUG REv., Aug. 29,1994 at Rx44.
18two extremes.
1.Deferral to FDA Determinations
Although arguments can be made for only reimbursing drugs ap-
proved by FDA for approved uses, this clearly places too much reliance on FDA.
FDA's mission regarding drugs is to protect the public against drugs which are
adulterated,86 misbranded,87 or otherwise not safe and eective88 for use. The
FFD&CA is not meant to substitute FDA's authority for the authority of med-
ical professionals. This is exemplied by the fact a generally accepted as safe
exemption to the new drug application requirement exists.89 lf FDA had in-
tended to regulate the practice of medicine, there would be no reason for a
generally accepted exception; the only acceptance that should matter would be
FDA's. Further, FDA has explicitly recognized that physicians may prescribe
approved drugs for unapproved uses.90 It would be costly and time-consuming
for FDA to certify every possible drug use's medical necessity.
It is also unclear whether a health plan, and certainly a government
health plan such as Medicaid, which requires coverage of medically necessary
items~ could legally refuse to cover a drug which had been recognized in the
medical literature as eective.91 Doctors are also much more likely to attempt
86FFD&CA I 501,21 US.C. ~ 351.
87FFD&CA x 502,21 U.S.C. x 352.
88FFD&CA x 201(p), 21 U.S.C. I 32l(p) (denition of new drug).
89Higgins, am nob 17. at 24.
90l~j, (citing 1974 case Kowaiski v. Rees (no citation available). ~L Wickline v. State,
741 P.2d 613,228 Cal. Rptr. 661 (App. CL 1986) (hokling that doctor, not state, was
not responsible when Medi-Cal approved fewer in-patientdays tban necessary);
United States v. Evers, 453 F. Supp. 1141 (D. Ala. 1978) (holding that pbysician
can prescribe drugs for unapproved uses). However, there are indications that
some private insurers have started to use FDA approval for a specied use as the
sine qua non for reimbursement
91Higgins, note 17, at 22.
19and discover inventive procedures and drugs to help their patient than the FDA
is to quickly approve such measures. This is why the medical literature is so
important.92
2.De1~rral to Doctors
The opposite extreme is equally untenable. Though the Medicare
statute states that there is a prohibition against federal interference with the
practice of medicine,93 health insurance reimbursement practices indisputably
aect physicians.94 In fact, this is precisely what is intended. To a certain
extent, a major aim of government run health insurance is to not rely solely
on physician discretion. In terms of cost control, it is essential that some-
one at some point beahictosaythatenoughisenough. Inthistimeoimitedpubli-
cresources,thereisnosensein reimbursing large amounts of public money for non-
cost-eective treatments and drugs which could be better spent elsewhere. This
is embodied in the Medicare reasonable and necessary standard.95
As managed care becomes more widespread, there is also the pos-
sibility not of deferring to doctors, but deferring to managed care organizations
to make determinations as to what is best for its clients. Because managed care
organizations receive xed payments for their clients and because they want to
retain their clients, they have incentives both to provide quality service and to
reduce costs. The question of how drugs should be covered under managed care
92~ Higgins, sum note 17, at 24.
9342 U.S.C.A. x1395.
94Richard E. Wild, Medicare Reimbursement for FDA Anproved Drugs:
Medicare's Answer to United States v. Eves, 40 FOOD DRUG COSM. U.
382,382(1985).
9542 U.S.C.A. x 1395(yXaXl) (West Strpp. 1994).
20is certainly something to consider in future public health pIans.96
3.Somewhere In-Between
Our present systems, and most of the suggestions for future re-
form, are somewhere in between these two extremes. All four of the schemes
examined above depart to some degree from reimbursing solely on the basis of
FDA approval. Similarly, none look solely to the doctor's discretion. Most look
primarily to FDA and to established compendia for most coverage decisions,
with exceptions. Medicare, for example, makes a specic statutory exception
for Group C cancer drugs. The schemes dier signicantly in where they place
the discretionary judgment in bordedine cases. Although Medicare's reasonable
and necessary standard gives the program an eective way to limit coverage,
discretionary decisions are made using the generally accepted medical practice
in local areas, either by judgment of the medical sta or the Medicare carner.
This may make patients nervous as they await decisions as to whether their
~nent is or is not covered.97 Further, as communications improve and as the
discernible dimnces existing between medical communities seem less reason-
able, this practice may come un~ question.98 Medicaid formularies present one
option, but they have been attacked when they don't keep up with current med-
ical practice.99 Both MCCA and HSA called for HCFA to s~ drug standards
for use (though MCCA precluded use of these standards for coverage reasons).
96Mark V. Pauly,, 24 SETONHALLL REV. 1271, 1285-88 (1994)
97For an example, look at the reported hesitation of Medicare carries, a recent
decisions to cover the anti-rejection drug FKSO6 f~r o-labea uses. Bryon Space,
~f~~IruaiImtfrag.Em1Ia.~. g~mua PITF. PUSr-43AZErrE, Sept. 7,1994, at A10 Bryan
Spice, , PITl~. POST-GA7ErFE, Aug. 31,1994, at B4.
98Coleman, jjin note 18 at 102.
99jj~ notes 75-76 ami accon~ianying text.
21Perhaps this is a logical place to look for coverage guidelines~ although at least
one commentator is skeptical of HCFA's resources to comprehensively decide
coverage issues.100
A further question is how experimental and investigational drugs
should be covered. While Medicare generally does not cover these drugs under
its reasonable and necessary standard, these drugs provide the only hope for
many terminal patients. This partly explains the Group C cancer drug excep-
tion. While the HSA planned a committee to examine prices of breakthrough
drugs, no mention was made of coverage issues for investigational and exper-
imental drugL A system should be devised to allow individuals desperate for
treatments to have some access (without the drug companies shifting the entire
development cost onto the public insurer).
C. How should over-the-counter drugs be treated?
The p side to investigational and experimental drug coverage is
coverage of over-the-counter (OTC) drugs. It is interesting to note that while
costs for prescription drugs have increased quickly over the last ten years, costs
have not similarly increased for nonprescription items.101 Aside from the ques-
tion of whether health care system costs could be saved by switching drugs
WOTC status,102 there are some who believe that increased coverage of pre-
scription drugs by insurance will result in increased switches of prescription
100CoIeman, note 18, at 102.
101I..etech, hun note 6, at 98.
102Peter B. Hutt, Drugs for Self4Aedication in tim Future, 19 DRUG INFO. J.
195,196-97(1985) (the political self-interests of pharmacists, physicians, and cfrug
conq,anies may mitigate against snoh a switch).
22drugs to OTC status.103 This may come either at the impetus of the man-
ufacturers104 or the public insurer, who desperately wants to reduce costs.105
If many drugs do switch to OTC status, this could lead to pressure to extend
insurance coverage to OTC drugs.106 Some states presently choose to cover
non-prescription drugs under their Medicaid plans.
Government reimbursement of drugs is likely to be an important
part of any future health carereformeort Itisinmanywaysanareawhichshouldbe-
coveredbyinsurancebutisnot Given that reimbursement may occur, it is impor-
tant to examine how the limits of this coverage will be dened. Coverage must
mesh with FDA drug approval, and must confront the physician's practice of
medicine. Cost-eectiveness and cost control are also important. By looking
at existing schemes for coverage of drugs under Medicare and Medicaid, as weil
some of the other recent eorts to propose a drug benet, we get some idea of
the questions and possible answers which a drug benet entails.
103Ricbard M. Cooper, 24 SETONHALLL REV. 1260,1260-61(1994).
104AS Cooper suggests, id. at 1261, though I agree with Hutt~ IU~I note 102, at
197 that this is ~uiIlkely.
105S~v~ example given in class (sorry, I tried to nd documentation, bs* came ~ short).
106Cooper, note 103, at 1263.
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